Anixa Biosciences receives notice of allowance for new patent from USPTO

Anixa Biosciences (ANIX) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for a new patent application covering its chimeric antigen receptor-T cell technology. The allowed claims in this patent encompass core methods and compositions that are fundamental to Anixa’s innovative CAR-T approach. Anixa’s CAR-T platform is specifically designed to address the long-standing challenges of applying CAR-T therapies to solid tumors, positioning the program as a potential breakthrough in immuno-oncology. This patent, along with others, was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences. Anixa’s CAR-T technology is currently in a clinical trial at Moffitt Cancer Center, treating recurrent ovarian cancer patients.